-
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)
Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Types of Glial Cells(Post)Microglia Astrocytes Oligodendrocytes Glial
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
Decoding the Language of Cells: Chemokine Signaling Pathways Unveiled(Post)Chemokines are small signaling proteins that play a crucial role in the immune system by directing the movement of cells, orchestrating immune responses, and maintaining tissue homeostasis. The
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
TGF-β/SMAD signalling(Page) Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask(Post)Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask Reliable results come from antibodies validated specifically for denatured western blot conditions: recombinant monoclonals or well-
6 pasos para el plegamiento de proteínas recombinantes en laboratorio(Post)Para recuperar la actividad biológica de proteínas recombinantes expresadas como cuerpos de inclusión, la vía más fiable combina una solubilización controlada con un replegamiento gradual, mediant
The EGFR/HER Family: Dimerisation, Ligand Independence & Resistance(Page) Ras signaling pathway(Post)A wide variety of cell surface receptors activate Ras GTPase, including the tyrosine receptor linked to the epidermal growth factor receptor (EGFR) (Wells 1999). Upon receptor stimulation, son o
Understanding Glutamate Receptors: Classification, Function, and Implications in Neurological Disorders(Post)Glutamate receptors are pivotal in mediating excitatory neurotransmission in the central nervous system (CNS), playing crucial roles in synaptic transmission, plasticity, learning, and memory. The
Microtubule and Mitosis review(Post)Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
NLRP3 Inflammasome and Pyroptosis: Pathway, Function and Assays(Post)The inflammasome is one of the few innate pathways that destroys the cell it activates. A macrophage that assembles NLRP3 has committed to a decision it cannot reverse: a priming signal through TLR4
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
Autophagy, Mitophagy and Immunity (Page) Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab